Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Colorcon
Moodys
McKinsey

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR OFIRMEV


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Ofirmev

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT02994940 ↗ Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen Completed University of California, Davis Phase 4 2017-08-28 Acetaminophen is frequently used as an adjunct for pain management in pediatric surgical patients. The drug is available in an over the counter, inexpensive oral form as well as a considerably more expensive intravenous form. This study will compare opioid requirements and acetaminophen plasma levels post operatively for two dosing regimens to compare oral versus intravenous routes given pre operatively.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Ofirmev

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01500109 ↗ Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair Completed Loma Linda University N/A 2011-11-01 The purpose of this investigator-initiated study is to determine whether acetaminophen is an effective pain reliever for primary cleft palate repair in children and possesses opioid sparing effects. Additionally, the investigators will determine if patients who receive acetaminophen have less opioid related side-effects. The study will have three study groups based on whether the patient receives Ofirmev® and opioids (Fentanyl and Morphine), oral acetaminophen elixir and opioids (Fentanyl and Morphine), or opioids (Fentanyl and Morphine) alone. Total opioid (Fentanyl and Morphine) consumption will be tracked for the intraoperative period and 24 hours after surgery for all patients within the study and converted to morphine equivalents.
NCT01520298 ↗ Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients Withdrawn Lancaster General Hospital Phase 3 2011-12-01 This research study is a prospective, randomized, blinded, placebo controlled trial evaluating the benefit of IV acetaminophen (Ofirmev™) as adjuvant analgesia in geriatric hip fracture patients. IV acetaminophen has received FDA approval. IV acetaminophen does not have the liver toxicity as oral acetaminophen. No oral acetaminophen will be administered. All patients diagnosed with a hip fracture aged at least 65 years and expected to undergo surgical intervention are eligible to participate. Hip fractures affect greater than 300,000 geriatric patients annually, representing the second leading cause of hospitalization for this patient population. Pain control in these patients is often problematic due to co-morbidities and changes in their pharmacokinetic and pharmacodynamic profiles. Subjects may receive the normal DVT prophylactic treatments post-op.
NCT01527942 ↗ Intravenous Acetaminophen Use With Bariatric Surgery on Morbidly Obese Patients Terminated Saint Francis Care N/A 2012-03-01 Bariatric patients usually require the use of either intravenous or oral opioid medications. The use of opioids, however, is often associated with side-effects such as nausea, sedation pruritus, urinary retention and respiratory depression with often delay patient discharge. This study makes use of intravenous acetaminophen , a non-opioid analgesic preoperatively to determine if this will decrease the use of opioids post-operatively for pain management in morbidly obese patients undergoing laparoscopic bariatric surgery.
NCT01544062 ↗ IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery Completed Mallinckrodt Phase 4 2012-07-01 Patients undergoing cardiac surgery experience significant postoperative pain, which may impact postoperative outcomes. The aim of this single center, double-blind, randomized, placebo controlled trial is to determine if intravenous (IV) acetaminophen will significantly decrease 24 hour postoperative opioid consumption.
NCT01544062 ↗ IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery Completed University of Washington Phase 4 2012-07-01 Patients undergoing cardiac surgery experience significant postoperative pain, which may impact postoperative outcomes. The aim of this single center, double-blind, randomized, placebo controlled trial is to determine if intravenous (IV) acetaminophen will significantly decrease 24 hour postoperative opioid consumption.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ofirmev

Condition Name

Condition Name for Ofirmev
Intervention Trials
Pain 9
Postoperative Pain 7
Pain, Postoperative 6
Acute Pain 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ofirmev
Intervention Trials
Pain, Postoperative 23
Acute Pain 5
Nausea 2
Cleft Palate 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ofirmev

Trials by Country

Trials by Country for Ofirmev
Location Trials
United States 80
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ofirmev
Location Trials
New York 12
Pennsylvania 9
California 8
Ohio 8
Texas 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ofirmev

Clinical Trial Phase

Clinical Trial Phase for Ofirmev
Clinical Trial Phase Trials
Phase 4 40
Phase 3 6
Phase 2 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ofirmev
Clinical Trial Phase Trials
Completed 36
Terminated 10
Unknown status 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ofirmev

Sponsor Name

Sponsor Name for Ofirmev
Sponsor Trials
Mallinckrodt 13
Nevakar, Inc. 2
Weill Medical College of Cornell University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ofirmev
Sponsor Trials
Other 70
Industry 18
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Dow
McKesson
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.